{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:09:26Z","timestamp":1781284166112,"version":"3.54.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ctrv.2025.102879","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T01:22:35Z","timestamp":1736040155000},"page":"102879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0817-5238","authenticated-orcid":false,"given":"Jinna","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-4862","authenticated-orcid":false,"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2025.102879_b0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/OP.21.00482","article-title":"Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions","volume":"18","author":"Sella","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"#cr-split#-10.1016\/j.ctrv.2025.102879_b0010.1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Breast Cancer Version 1.2024 2024 [updated 2024"},{"key":"#cr-split#-10.1016\/j.ctrv.2025.102879_b0010.2","unstructured":"cited 2024. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419."},{"issue":"2","key":"10.1016\/j.ctrv.2025.102879_b0015","first-page":"177","volume":"32","year":"2022","journal-title":"Oncology"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102879_b0020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","article-title":"Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression","volume":"34","author":"Burstein","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102879_b0025","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.2015.65.3493","article-title":"Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?","volume":"34","author":"Papakonstantinou","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102879_b0030","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2006.08.8534","article-title":"Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102879_b0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12032-012-0354-1","article-title":"Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients","volume":"30","author":"Aydiner","year":"2013","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102879_b0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10549-024-07323-9","article-title":"Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study","volume":"206","author":"Chen","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2025.102879_b0045","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djae115","article-title":"Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer","author":"Lin","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102879_b0050","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102879_b0055","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","article-title":"Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102879_b0060","doi-asserted-by":"crossref","unstructured":"Burns E, Koca E, Xu J, McLean E, Lee R, Patel T, et al. Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy. Oncologist. 2021;26(6):e936-e942.","DOI":"10.1002\/onco.13722"},{"key":"10.1016\/j.ctrv.2025.102879_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103818","article-title":"Clinical significance of serum estradiol monitoring in women receiving adjuvant aromatase inhibitor for hormone receptor-positive early breast cancer","volume":"78","author":"Dai","year":"2024","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102879_b0070","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.18.00296","article-title":"Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial","volume":"37","author":"Dellapasqua","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102879_b0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41523-024-00680-0","article-title":"Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy","volume":"10","author":"Tesch","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102879_b0080","first-page":"705","article-title":"Factors-associated with short-term effect and long-term survival of ovarian function suppression in estrogen receptor positive breast cancer: A retrospective analysis","volume":"32","author":"Liu","year":"2022","journal-title":"China Oncology"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102879_b0085","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.clbc.2023.03.009","article-title":"Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use","volume":"23","author":"Fleege","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2025.102879_b0090","article-title":"Predictors of Incomplete Ovarian Function Suppression (OFS) in Adolescent and Young Adult (AYA) Women with Hormone Receptor Positive (HR+) Breast Cancer","author":"Anandan","year":"20238352","journal-title":"Cancer Res"},{"issue":"15 SUPPL","key":"10.1016\/j.ctrv.2025.102879_b0095","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1200\/JCO.2021.39.15_suppl.6574","article-title":"Ovarian function suppression in premenopausal patients with concurrent endocrine therapy use","volume":"39","author":"Grogan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102879_b0100","doi-asserted-by":"crossref","unstructured":"Kendzierski DC, Schneider BP, Kiel PJ. Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: ARetrospective Review. Clin Breast Cancer. 2018;18(5):e939-e942.","DOI":"10.1016\/j.clbc.2018.04.005"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102879_b0105","article-title":"Goserelin Ovarian Ablation Failure in Premenopausal Women With Breast Cancer","volume":"13","author":"Gupta","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102879_b0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jogoh.2018.03.002","article-title":"Ovarian suppression failure during GnRH agonist treatment: A report of three breast cancer patients","volume":"47","author":"de Ciantis","year":"2018","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"10.1016\/j.ctrv.2025.102879_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.04.022","article-title":"Current strategies for quantification of estrogens in clinical research","volume":"192","author":"Denver","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"17","key":"10.1016\/j.ctrv.2025.102879_b0120","doi-asserted-by":"crossref","first-page":"10665","DOI":"10.1021\/acsami.5b10996","article-title":"Highly Sensitive Detection of Hormone Estradiol E2 Using Surface-Enhanced Raman Scattering Based Immunoassays for the Clinical Diagnosis of Precocious Puberty","volume":"8","author":"Wang","year":"2016","journal-title":"ACS Appl Mater Interfaces"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102879_b0125","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0178","article-title":"A method to detect fulvestrant interference in estradiol in breast cancer patients","volume":"12","author":"Brito","year":"2023","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102879_b0130","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/0004563216674031","article-title":"Falsely elevated serum oestradiol due to exemestane therapy","volume":"54","author":"Mandic","year":"2017","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102879_b0135","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41416-019-0378-9","article-title":"Oestradiol measurement during fulvestrant treatment for breast cancer","volume":"120","author":"Owen","year":"2019","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102879_b0140","first-page":"1101","article-title":"Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study","volume":"3","author":"Johannessen","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102879_b0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3343\/alm.2022.42.1.3","article-title":"Hormone Immunoassay Interference: A 2021 Update","volume":"42","author":"Ghazal","year":"2022","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.ctrv.2025.102879_b0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejca.2019.10.015","article-title":"Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer","volume":"126","author":"Samuel","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102879_b0155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2193-1801-2-5","article-title":"Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients","volume":"2","author":"Jaque","year":"2013","journal-title":"Springerplus"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102879_b0160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-024-00614-w","article-title":"Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer","volume":"10","author":"McCann","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2025.102879_b0165","unstructured":"Committee of Breast Cancer Society CA-CA. Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer (2024 edition). CHINA ONCOLOGY. 2024;34(3):324-342."},{"key":"10.1016\/j.ctrv.2025.102879_b0170","unstructured":"Expert consensus on the diagnosis and treatment of young breast cancer in China (2022 Edition). Zhonghua Yi Xue Za Zhi. 2023;103(6):387-403."},{"issue":"4","key":"10.1016\/j.ctrv.2025.102879_b0175","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4143\/crt.2016.463","article-title":"Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors","volume":"49","author":"Suh","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102879_b0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12282-016-0691-6","volume":"24","author":"Kurebayashi","year":"2017","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ctrv.2025.102879_b0185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2017.10.001","article-title":"The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer","volume":"87","author":"Anderson","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.102879_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.629666","article-title":"Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis","volume":"11","author":"Dong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.102879_b0195","doi-asserted-by":"crossref","unstructured":"Coyne K, Silverman P, Liu JH. Oral GnRH Antagonist Ovarian Suppression After Escape From GnRH Agonist in Breast Cancer Patients. Clin Breast Cancer. 2020;20(5):e551-e554.","DOI":"10.1016\/j.clbc.2020.05.011"},{"key":"10.1016\/j.ctrv.2025.102879_b0200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fendo.2017.00110","article-title":"Gonadotropin-Releasing Hormone and Its Role in the Enteric Nervous System","volume":"8","author":"Ohlsson","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ctrv.2025.102879_b0205","article-title":"Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer","author":"Dowsett","year":"199214","journal-title":"Clin Ther"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102879_b0210","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.2015.62.3728","article-title":"Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer","volume":"34","author":"Dowsett","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102879_b0215","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.breast.2005.08.019","article-title":"The biology of steroid hormones and endocrine treatment of breast cancer","volume":"14","author":"Dowsett","year":"2005","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102879_b0220","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/me.2006-0253","article-title":"Reciprocal cross talk between gonadotropin-releasing hormone (GnRH) and prostaglandin receptors regulates GnRH receptor expression and differential gonadotropin secretion","volume":"21","author":"Naor","year":"2007","journal-title":"Mol Endocrinol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102879_b0225","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102879_b0230","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102879_b0235","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.18.01967","article-title":"Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT","volume":"38","author":"Pagani","year":"2020","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ctrv.2025.102879_b0240","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1200\/JCO.23.00557","article-title":"Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial","volume":"41","author":"Baek","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102879_b0245","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.critrevonc.2016.08.009","article-title":"Aromatase inhibitors in premenopause: Great expectations fulfilled?","volume":"107","author":"Torrisi","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102879_b0250","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","article-title":"Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102879_b0255","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/annonc\/mds464","article-title":"Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane","volume":"24","author":"Guerrero","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102879_b0260","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/94.8.606","article-title":"Breast Cancer Collaborative G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies","volume":"94","author":"Key","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102879_b0265","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-19-3091","article-title":"Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor alpha","volume":"26","author":"Ingle","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102879_b0270","article-title":"Estrogen levels in premenopausal patients (PTS) with hormonereceptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis","volume":"79","author":"Bellet","year":"2019","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102879_b0275","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102879_b0280","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.ejca.2012.10.004","article-title":"The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer","volume":"48","author":"Cardoso","year":"2012","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1016\/j.ctrv.2025.102879_b0285","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102879_b0290","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2022.07.007","article-title":"ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)","volume":"33","author":"Paluch-Shimon","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102879_b0295","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.524","article-title":"Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa)","author":"Tesch","year":"20224016524","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102879_b0300","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1210\/jc.2013-2905","volume":"99","author":"Stanczyk","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"03","key":"10.1016\/j.ctrv.2025.102879_b0305","first-page":"238","article-title":"To standardize the sex hormone laboratory reports of breast cancer and rationalize the menopausal criteria of using AIs","volume":"6","author":"Song","year":"2012","journal-title":"Chinese Journal of Breast Disease (Electronic Edition)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102879_b0310","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1186\/s12885-018-4843-2","article-title":"An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project","volume":"18","author":"Pelizzari","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102879_b0315","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12885-017-3208-6","article-title":"Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?","volume":"17","author":"Oberguggenberger","year":"2017","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1016\/j.ctrv.2025.102879_b0320","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","article-title":"Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial","volume":"29","author":"Pfeiler","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102879_b0325","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1634\/theoncologist.2015-0183","article-title":"Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram","volume":"20","author":"Barnabei","year":"2015","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.ctrv.2025.102879_b0330","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cncr.28942","article-title":"Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients","volume":"120","author":"Su","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.102879_b0335","doi-asserted-by":"crossref","unstructured":"Kalinsky K, Barlow WE, Pathak HB, Gralow JR, Albain KS, Hayes DF, et al. Correlation of serum anti-M\u00a8ullerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). ASCO2024. p. 505-505.","DOI":"10.1200\/JCO.2024.42.16_suppl.505"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102879_b0340","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s12282-015-0637-4","article-title":"Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer","volume":"23","author":"Noguchi","year":"2016","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102879_b0345","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-010-1332-y","article-title":"Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer","volume":"126","author":"Masuda","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2025.102879_b0350","doi-asserted-by":"crossref","unstructured":"Kelly CM, Bennett KE, Cahir C, Eisen A, Pusztai L. Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO. JCO Oncol Pract. 2024:Op2400502.","DOI":"10.1200\/OP-24-00502"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T03:29:51Z","timestamp":1738812591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":71,"alternative-id":["S0305737225000015"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102879","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102879"}}